Evidence map›Paper›PMID 34383114›Full record

ArticleJournal of neurology2022

Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.

Haojie Xie, Yingzhe Shao, Juan Du, Yajun Song, Yanfei Li, Ranran Duan, Yaobing Yao, Zhe Gong, Junfang Teng, Yanjie Jia

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Glial cells and neurologic autoimmune disorders.Frontiers in cellular neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Haojie XieDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yingzhe ShaoDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Juan DuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yajun SongDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanfei LiDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ranran DuanDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yaobing YaoDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhe GongDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junfang TengDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanjie JiaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiayanjie1971@zzu.edu.cn.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to compare the clinical data, laboratory findings, and imaging characteristics of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin 4 antibody (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD), as detailed comparative analyses of laboratory data for both diseases are rare.

methodsOur retrospective study compared the clinical data, laboratory findings, and imaging characteristics of 118 AQP4-positive patients with first-episode NMOSD and 25 patients with first-episode MOGAD. Logistic regression was used to determine the factors that differentiated MOGAD and AQP4-positive NMOSD.

resultsThere were significant differences in age, symptoms, recurrence rate, laboratory indicators, and imaging examinations between patients with MOGAD and patients with AQP4-positive NMOSD. Patients with MOGAD were younger and had higher levels of uric acid than those with AQP4-positive NMOSD. The proportion of cortical gray matter/juxtacortical white matter lesions was significantly higher in the MOGAD group than in the NMOSD group. Logistic regression revealed that young age [odds ratio (OR) = 0.947, 95% confidence interval (CI) = 0.905-0.99], high uric acid level (OR = 1.016, 95% CI = 1.006-1.027), and cortical gray matter/juxtacortical white matter involvement (OR = 3.889, 95% CI = 1.048-14.442) were significantly related to MOGAD.

conclusionThe multivariate analysis of the present study demonstrated that age, uric acid level, and the presence of lesions in the cortical gray matter/juxtacortical white matter can aid in distinguishing patients with AQP4-positive NMOSD from those with MOGAD. These factors may also aid in determining which patients should be tested for antibodies.

Indexed as

Aquaporin 4Demyelinating Autoimmune Diseases, CNSNeuromyelitis OpticaAutoantibodiesHumansMyelin-Oligodendrocyte GlycoproteinRetrospective StudiesAquaporin 4AutoantibodiesMyelin-Oligodendrocyte GlycoproteinAquaporin 4Gray matterMyelin oligodendrocyte glycoproteinNeuromyelitis optica spectrum disorderUric acidWhite matter

Identifiers

PMID34383114
OpenAlexW3191705501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.